Healthcare
Sino Biopharmaceutical Limited(SBHMY)
Live Price
Offline$12.07
+7.05% today
1Y Change
+27.27%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $84.44B
- Revenue Growth
- +7.3%
- EPS Growth
- -35.0%
- Dividend Yield
- 1.7%
Coverage: 254 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sino Biopharmaceutical Limited (SBHMY) is a Healthcare stock with a market cap of $84.44B and listed on OTC. The stock last traded around $12.06 and up 27.3% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +7.3%, EPS growth of -35.0%, a dividend yield of 1.7%. What stands out right now is revenue +7.3%, EPS -35.0%, free cash flow +45.4% with operating margin 20.6% and ROIC 7.4%. The dividend is present but secondary, with a yield around 1.7%. Valuation is more restrained than many high-expectation growth names at P/E 23.5 and price/sales 3.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SBHMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.3% vs +7.6% peer median
Operating Margin
Near sector median
+20.6% vs +19.4% peer median
P/E
Below sector median
23.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 18, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.3% and EPS is at -35.0%, with operating margin around 20.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.7%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 18, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Aug 15, 2025 | โ | +0.0% | +0.0% | +3.4% |
2025 Jun 5, 2025 | โ | +0.0% | +0.0% | +71.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SBHMY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SBHMY Max Drawdown
-44.10%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SBHMY and SPY.
Company Overview
Sino Biopharmaceutical Limited
Other OTC
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
- Leadership
- S. Y. Tse
- IPO Date
- Sep 5, 2017
- Employees
- 24.4k
- Street Address
- Office Tower
- Mailing
- Wan Chai
- Region
- Wan Chai, HK
- Reporting Currency
- USD
- Investor Line
- 852 2802 9886
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.5
- EV/EBITDA
- 18.5
- Price/Sales
- 3.5
- Price/Book
- 2.8
Growth
- Revenue
- +7.3%
- EPS
- -35.0%
- Free Cash Flow
- +45.4%
Profitability
- Gross Margin
- 82.0%
- Operating Margin
- 20.6%
- Net Margin
- 15.1%
- ROE
- 11.2%
- ROIC
- 7.4%
Balance Sheet
- Debt/Equity
- 0.52
- Current Ratio
- 1.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.